MD Education

Thor Halfdanarson: Lot to unpack from the excellent NORDIC NEC 2 Study

Thor Halfdanarson, Medical Oncologist at the Mayo Clinic, shared a post on X about recent article Halfdan Sorbye and colleagues authored:

“Lot to unpack from the excellent NORDIC NEC2.
– ORR: 31% for NEC (mostly plat/eto) – this is NOT SCLC
– ORR: 27% for G3 NETs (mostly TMZ-based)
– Immediate progression: 41% of NECs, 21% G3 NETs
– PFS: 3.4 m NEC; 7.4 G3 NET
NECs are really bad cancers!”

Thor Halfdanarson

Title: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study

Authors: Halfdan Sorbye, Geir Olav Hjortland, Lene Weber Vestermark, Morten Ladekarl, Johanna Svensson, Anna Sundlöv, Eva Tiensuu Janson, Herish Garresori, Eva Hofsli, Christian Kersten, Hege Elvebakken, Per Pfeiffer, Siren Morken, Jorg Assmus, Inger Marie Bowitz Lothe, Elizaveta Tabaksblat, Ulrich Knigge, Anne Couvelard, Aurel Perren, Seppo W. Langer

Read Full Article.
Thor Halfdanarson

More posts featuring Thor Halfdanarson on OncoDaily.

Anna Sundlöv Anne Couvelard Aurel Perren cancer Christian Kersten Elizaveta Tabaksblat Eva Hofsli Eva Tiensuu Janson Geir Olav Hjortland Halfdan Sorbye Hege Elvebakken Herish Garresori Inger Marie Bowitz Lothe Johanna Svensson Jorg Assmus Lene Weber Vestermark Morten Ladekarl OncoDaily Oncology Per Pfeiffer Seppo W. Langer Siren Morken Thor Halfdanarson Ulrich Knigge